Synthetic applications of boryl carboxylates

2019 年春季，我们发现了羧酸硼酯 (CBA)，这是一类具有尚未开发的合成潜力的新型分子。我们随后申请了专利来保护这种物质组合物。 CBA 技术很快引起了默克公司的注意，我们发起了合作，以了解这种新化学物质的潜在应用范围。因此，我们最近与默克公司在《Angewandte Chemie》上发表了一篇联合论文。我们还获得了 NSERC 的市场评估资金，使我们能够保留 Adventus Research 的服务。 Adventus 的 G. Svoboda 博士进行了彻底的市场评估研究。当前的 I2I 应用程序考虑了该报告中的主要信息，并重点关注将进一步降低我们的技术风险的应用程序，因为它已经足够成熟。借助这份报告，我们现在有了加强 CBA 技术商业价值的具体步骤。其中包括开发一系列 CBA 衍生物，以及展示这些分子在合成具​​有挑战性的杂环化合物中的优越性能。我们的合作伙伴（Merck、Eurofins Alphora 和 MilliporeSigma）非常适合帮助我们扩大专利主张并使该技术更接近许可。

In the Spring of 2019, we discovered boryl carboxylates (CBA), a new class of molecules with untapped synthetic potential. We subsequently applied for a patent to protect this composition of matter. The CBA technology quickly attracted the attention of Merck and we initiated a collaboration in order to understand the scope of potential applications of this new chemistry. As a result, we recently published a joint paper with Merck in Angewandte Chemie. We also received market assessment funding from NSERC, allowing us to retain the services of Adventus Research. Dr. G. Svoboda of Adventus has carried out a thorough market assessment study. The present I2I application considers the main messages from that report and focuses on the applications that will further de-risk our technology now that it is sufficiently mature. With the help of this report, we now have specific steps to strengthen the commercial value of the CBA technology. These include the development of a range of CBA derivatives as well as the demonstration of superior properties of these molecules in the synthesis of challenging heterocycles. Our partners (Merck, Eurofins Alphora, and MilliporeSigma) are ideally suited to help us broaden patent claims and position this technology closer to licensing.